FPAS
ALLO icon

Focus Partners Advisor Solutions’s Allogene Therapeutics ALLO Stock Holding History

Focus Partners Advisor Solutions’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,730
Closed -$43.3K – 1253
2026
Q1 		$43.3K Buy
+17,730
New +$35.5K ﹤0.01% 1225

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Focus Partners Advisor Solutions's ALLO Position: Q2 2026 in Review

Focus Partners Advisor Solutions sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 17,730 shares — an estimated $43.3K sold.

Focus Partners Advisor Solutions first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $43.3K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Focus Partners Advisor Solutions reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Advisor Solutions sold 17,730 Allogene Therapeutics shares in Q2 2026, an estimated $43.3K.
  • Focus Partners Advisor Solutions first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
  • Focus Partners Advisor Solutions's Allogene Therapeutics position peaked at $43.3K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.